POSITION
Lead
BOARD
Lead
EXIT
Acquired by Swiss-based Therachon Holding AG in September 2018
GLyPharma Therapeutic Inc. (GlyPharma) was a new company created in Montreal for the purpose of a strategic partnership between Ferring Pharmaceuticals (Ferring), a European pharmaceutical company, Fonds de solidarité FTQ and CTI Life Sciences Fund aimed at developing a Ferring asset by importing it to the province of Quebec. GlyPharma was granted by Ferring, an exclusive worldwide license for development and commercialization. The compound a long-acting GLP-2 receptor agonist, was at pre-clinical stage at the time of creation of the company. It was tested for a first-in-class indication in supportive care in oncology but later on was successfully developed in Short Bowel Syndrome a G/I indication which warranted Orphan Drug designation. The company was purchased by Swiss-based Therachon Holding AG in September 2018.